Enliven Therapeutics Inc. Cash Flow-to-Debt Ratio
Enliven Therapeutics Inc. cash flow-to-debt ratio. Enliven Therapeutics Inc. (ELVN) has a Cash Flow-to-Debt Ratio of -1.23x as of June 2026, meaning its operating cash flow of $-18.53 Million could theoretically repay -1% of its total liabilities ($15.07 Million) in one year. See Enliven Therapeutics Inc. (ELVN) flexibility index to measure the company's free cash flow as a share of total liabilities.
CF-to-Debt Ratio
Operating Cash Flow
Total Liabilities
Data as of
Cash Flow-to-Debt Ratio of Enliven Therapeutics Inc. (2017–2025)
Cash flow-to-debt ratio of Enliven Therapeutics Inc. from 2017 to 2025. Historical debt coverage capacity for Enliven Therapeutics Inc. across 9 annual periods. See Enliven Therapeutics Inc. (ELVN) net asset quality to measure how much of total assets are equity-financed.
Enliven Therapeutics Inc. Cash Flow-to-Debt Ratio by Year (2017–2025)
Enliven Therapeutics Inc. cash flow-to-debt ratio by year from 2017 to 2025. Year-by-year debt coverage analysis for Enliven Therapeutics Inc.. For the full cash flow conversion analysis, see cash efficiency ratio of Enliven Therapeutics Inc..
| Year | CF-to-Debt Ratio | Operating CF (USD) | Total Liabilities | YoY Change |
|---|---|---|---|---|
| 2025 | -4.22x | $-70.30 Million | $16.68 Million | ▲ +8.3% |
| 2024 | -4.60x | $-73.19 Million | $15.91 Million | ▼ -94.9% |
| 2023 | -2.36x | $-61.27 Million | $25.96 Million | ▼ -1078.1% |
| 2022 | -0.20x | $-32.08 Million | $160.12 Million | ▲ +93.2% |
| 2021 | -2.96x | $-19.13 Million | $6.47 Million | ▼ -122.3% |
| 2020 | -1.33x | $-8.53 Million | $6.41 Million | ▲ +73.3% |
| 2019 | -4.99x | $-21.88 Million | $4.38 Million | ▼ -4.2% |
| 2018 | -4.79x | $-8.78 Million | $1.83 Million | ▲ +19.0% |
| 2017 | -5.91x | $-8.79 Million | $1.49 Million | — |